Approximately 50% of severe asthma patients have eosinophilic inflammation. Elevated eosinophil counts (blood and sputum) are associated with several clinical features including severe airflow limitation, decreased symptom control and increased risk for exacerbations and hospitalizations, as well as other outcomes. Therefore, Severe Eosinophilic Asthma (SEA) burden to patients includes decreased lung function and physical activity, missed days of work and school, and increased mortality.

This program will review SEA:

  • Definitions and guideline recommendations for management
  • The role of eosinophils in SEA and outcomes, including exacerbations, and
  • Comorbidities, with a focus on Chronic rhinosinusitis with nasal polyps.

At the end of the program, attendees should be able to:

  • Understand the burden of Severe Eosinophilic Asthma (SEA)
  • Discuss the guidelines for appropriate SEA treatments
  • Discuss the role of eosinophils and their link to patient outcomes, and
  • Recognize the comorbidities associated with SEA.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.